Biocryst Pharmaceuticals (BCRX) Total Debt Growth (3y) (2014 - 2026)
Biocryst Pharmaceuticals (BCRX) Total Debt Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.86 Bn | 42.90 Bn | - | 15.43% |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.54 Bn | 2.15 Bn | -7.08% |
| 3 | Zoetis | 31.46 Bn | 29.79 Bn | 1.05 Bn | 11.33% |
| 4 | Takeda Pharmaceutical | 28.57 Bn | 22.77 Bn | 5.10 Bn | -3.67% |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -10.43% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.71 Bn | 11.18 Bn | 798.00 Mn | -13.72% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 92.83% |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | 14.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.42% |
| Mar 31, 2026 | 23.27% |
| Dec 31, 2025 | -45.04% |
| Sep 30, 2025 | 1.20% |
| Jun 30, 2025 | 24.45% |
| Mar 31, 2025 | 35.61% |
| Dec 31, 2024 | 5.24% |
| Sep 30, 2024 | 38.04% |
| Jun 30, 2024 | 39.31% |
| Mar 31, 2024 | 39.57% |
| Dec 31, 2023 | 38.65% |
| Sep 30, 2023 | 86.36% |
| Mar 31, 2023 | 66.32% |
| Dec 31, 2022 | 195.03% |
| Sep 30, 2022 | 64.73% |
| Jun 30, 2022 | 42.59% |
| Mar 31, 2022 | 41.39% |
| Dec 31, 2021 | 115.11% |
| Sep 30, 2021 | 64.04% |
| Jun 30, 2021 | 85.08% |